Related Experiment Video
Updated: Jun 4, 2026

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
Published on: January 26, 2019
Progress in enterovirus D68-neutralizing antibodies and vaccines
Liting Wang1, Jun Shen1,2
1Department of Infectious Disease, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
None:
Enterovirus D68 (EV-D68) causes severe respiratory diseases and acute flaccid myelitis (AFM), for which no licensed vaccines or therapeutics are currently available. Neutralizing antibodies (nAbs) block infection via binding capsid epitopes. This review summarizes the EV-D68 antigenic structure, nAb mechanisms (receptor blockade and conformational disruption), therapeutic prospects of nAbs, and vaccine progress (inactivated, virus-like particle [VLP], and nucleic acid). Key challenges, like antigenic drift and blood-brain barrier (BBB) penetration, are also highlighted to guide countermeasure development.
Related Concept Videos
Poliomyelitis
Respiratory Syncytial Virus Disease
Vaccinations
Vaccines
